Peak Retirement Planning Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 5,748 shares of the company's stock, valued at approximately $833,000.
Several other hedge funds also recently added to or reduced their stakes in the stock. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $32,000. Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $33,000. Finally, Bernard Wealth Management Corp. purchased a new position in Johnson & Johnson in the 4th quarter valued at $36,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Down 0.5%
Shares of JNJ stock traded down $0.72 on Wednesday, reaching $152.53. 2,573,172 shares of the stock were exchanged, compared to its average volume of 7,940,242. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The stock has a market cap of $367.01 billion, a P/E ratio of 22.94, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a 50 day moving average of $154.85 and a two-hundred day moving average of $153.65.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date is Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.
Analyst Ratings Changes
Several analysts have recently weighed in on the stock. Raymond James lowered their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Bank of America decreased their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $170.88.
Read Our Latest Report on JNJ
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
